132907-72-3

Nasea was launched in Japan for chemotherapy-induced emesis. Nasea was prepared by a four step sequence via the Vilsmeier-type coupling of 1- methylindole and 5-( 1- pyrrolidoncarbonyl)-4,5,6,7-tetrahydro-Hl -benzimidazole hydrochloride. The antiemetic activity arises because it is a potent 5-HT3 receptor antagonist that is i.v. and orally active. The (R)-isomer was found to be 100 times more potent than the (S)-isomer. It was able to inhibit cisplatin-induce emesis and was 8670 times more potent than netoclopramide.

White Solid

Yamanouchi (Japan)

Selective serotonin 5HT3, receptor antagonist; structurally different from Ondansetron (O655000), Granisetron (G780000). Antiemetic.

ChEBI: Ramosetron hydrochloride is a member of indoles.

Nasea

Ramosetron is a tetra hydrobenzimidazole derivative, containing an indole ring. It inhibits colon contraction mediated by serotonin, competitively.

Store at -20°C